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Tracing of neurons plays an essential role in elucidating neural
networks in the brain and spinal cord. Cholera toxin B subunit (CTB)
is already widely used as a tracer although its use is limited by
the need for immunohistochemical detection. A new construct
incorporating non-canonical azido amino acids (azido-CTB) offers
a novel way to expand the range and flexibility of this neuronal
tracer. Azido-CTB can be detected rapidly in vivo following intra-
muscular tongue injection by ‘click’ chemistry, eliminating the need
for antibodies. Cadmium selenide/zinc sulfide (CdSe/ZnS) core/shell
nanoparticles were attached to azido-CTB by strain-promoted
alkyne–azide cycloaddition to make a nano-conjugate. Following
tongue injections the complex was detected in vivo in the brainstem
by light microscopy and electron microscopy via silver enhancement.
This method does not require membrane permeabilization and so
ultrastructure is maintained. Azido-CTB offers new possibilities to
enhance the utility of CTB as a neuronal tracer and delivery vehicle
by modification using ‘click’ chemistry.
Cholera toxin produced by Vibrio cholerae is usually an infec-
tious agent of the gut, but the toxin also has the potential to be
developed for more versatile tracing and targeting of neurons.
It is formed of two main parts: the catalytically active A subunit
and the non-toxic pentamer of B subunits (CTB) that facilitate
cell entry via binding ganglioside GM1.1,2 GM1 is ubiquitously
expressed in vertebrates but is found in high relative abundance in
the nervous system, including in the periphery of motor neurons at
the neuro-muscular junction; for this reason CTB has been used
extensively as a neuronal tracer.3–6 It is usually detected via
antibody-mediated detection using fluorescence or 30-Diamino-
benzidine (DAB) immunohistochemistry,7–9 but direct fluorophore
conjugates are also available10,11 as well as CTB–horseradish
peroxidase (HRP) conjugates for detection via peroxidase
chemistry.4,12 The ability to detect the tracer directly without
the need of antibodies is advantageous. It does not require an
amplification step and so the labelling process is quicker, and
cheaper as no antibodies are required. Detecting proteins
without immunohistochemistry also provides more scope for
labelling multiple proteins without the need to consider cross-
reactivity of primary and secondary antibodies as well as
removing issues with antibody batch variability and limited
shelf-life. Existing fluorescein–CTB conjugates are prone to
bleaching, CTB–HRP conjugates are not compatible with
immunofluorescence methods and neither enables easy detec-
tion by electron microscopy as membranes must be permeabi-
lised to enable detection.
One method of detecting proteins without using antibodies
is to use a bioorthogonal reaction such as copper-catalysed
azide–alkyne cycloaddition (CuAAC) commonly referred to as
‘click chemistry’.13–15 As the azide group is small it can be
incorporated into probe molecules without interfering with
their behaviour in live organisms, while providing the oppor-
tunity for subsequent conjugation to fluorescent probes. Alter-
natively, strain-promoted azide–alkyne cycloaddition (SPAAC)
allows preparation of conjugates under copper-free conditions
that are suitable for use in live cells and animals.16–18 Azide-
functionalised amino acids can be incorporated into proteins
using the methionine surrogate azidohomoalanine (Aha).19,20
In methionine-depleted cultures, Aha is activated by methionyl-
tRNA synthetase of methionine auxotroph Escherichia coli and
replaces methionine in translated proteins. In this communi-
cation we report a novel azido-CTB toxoid and demonstrate its
utility for neuronal tracing in vivo. Azido-CTB can be made in
any lab with protein production facilities and a variety of
molecules may be readily conjugated in a site-specific manner
to suit individual needs.
The isosteric replacement of methionine with Aha at the
surface of CTB required the creation of a new mutant toxoid.
Three sequential rounds of site-directed mutagenesis were used
to replace all the native methionine residues with leucines
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(M37L, M68L, M101L) and a surface exposed lysine residue with
methionine (K43M) (Fig. S1, ESI†). As the K43M mutation is on
the non-binding face of the protein (Fig. 1a), future chemical
modifications at this site were predicted not to interfere with
CTB–GM1 binding. Methionine auxotroph E. coli B834 Gold
(DE3) cells were transformed with the new construct, pSAB2.3
(Azido), and azido-CTB was overexpressed using a defined
growth medium supplemented with Aha.19–21 The azido-CTB
was purified using Ni-affinity chromatography and size exclu-
sion chromatography before analysis by SDS-PAGE and mass
spectrometry (Fig. S2, ESI†). For the wild type CTB protein, the
tetra-mutant CTB is sufficiently stable to migrate as a pentamer
during SDS-PAGE unless the sample has been boiled prior to
loading (Fig. 1b). While the native CTB normally gives rise to a
protein band around 45 kDa on a gel, azido-CTB is more
negatively charged than native CTB which likely explains why
it ran faster (apparent mass o40 kDa).
The ability of the purified azido-CTB protein to enter motor
neurons, transport in a retrograde manner to the brainstem
and to be detected in vivo via CuAAC, was tested using tongue
injections in mice. Azido-CTB successfully traced the motor
neurons of the hypoglossal nucleus that innervate the tongue; it
was detected using CuAAC with a biotinylated alkyne (Kerafast)
followed by Alexa-555 labelled streptavidin (streptavidin-555) in
paraformaldehyde-fixed brain tissue (Fig. 2b–cii). Streptavidin
labelling (shown in red) overlapped with immunohisto-
chemical detection for CTB using an anti-CTB primary antibody
and secondary antibody labelled with Alexa-488), it was
detected in the same cells and to the same extent (Fig. 2a–ci).
Control brainstem slices with no azido-CTB injection under-
going the click reaction and detection with streptavidin-555
gave no positive cells, verifying that the signal in injected tissue
is from azido-CTB (Fig. 2d). Azido-CTB can therefore be used as
a neuronal tracer. If used in conjunction with immunohisto-
chemistry to identify other proteins such as ion channels and
receptor subunits within the tissue, it will reduce limitations
to the primary antibody species that can be used since CTB is
detected without antibodies. Furthermore, azido-CTB has the
potential to be used to make a fluorescently tagged tracer for
delivery with any fluorescent molecule containing an alkyne group.
To further extend the flexibility of azido-CTB, we used
its azide moiety for conjugation with nanoparticles prior to
neuronal tracing. Correlative light and electron microscopy
provides a powerful and complementary alternative to immuno-
histochemistry for studying sub-cellular localisation of probes.
In this context, targeted nanoparticles can be used as nucleation
sites for deposition of silver to facilitate their detection without
the need to permeabilise the tissue. We therefore investigated the
conjugation of CdSe/ZnS core/shell nanoparticles to azido-CTB
Fig. 1 Design and structure of azido-CTB. (a) Crystal structure of CTB
(red) bound to GM1 (black). Residue K43 (yellow). (b) SDS-PAGE gel
(12% acrylamide) of azido-CTB elution fraction after Ni-NTA column (left
to right: molecular weight markers; boiled azido-CTB; non-boiled sample
showing pentameric azido-CTB. (c) Cartoon showing cycloaddition of
azido-CTB with (d) a biotin-functionalised alkyne.
Fig. 2 Azido-CTB as a neuronal tracer detected by CuAAC. (a) Whole
brainstem section stained with anti-CTB antibody (green), hypoglossal
nucleus shown in white box. (b and c) Hypoglossal nucleus stained with
anti-CTB antibody (green, b-ci), CuAAC (red, b-cii) and merged (b-ciii).
(d) Control brainstem slice from non-injected mouse stained with the
nuclear marker DAPI (blue, di), CuAAC (red, dii) and merged (diii). Scale
bars: a = 500 mm; b = 50 mm; c = 10 mm; d = 100 mm.
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and their ability to target neurons in vivo. The nanoparticles were
first functionalised with a ligand mixture of dihydrolipoic acid
(DHLA)-PEG11-cyclooctyne and a DHLA-PEGB15-OMe spacer via
cap-exchange at a total ligand :nanoparticle molar ratio of
3000 : 1, with 10% or 25% of the ligands being DHLA-PEG11-
cyclooctyne ligand (Fig. 3).22–24 Azido-CTB was then directly
conjugated to the nanoparticles by SPAAC as confirmed by gel
electrophoresis (ESI,† Fig. S3). Site-specific biorthogonal label-
ling of CTB with the nanoparticles means that the binding
face of CTB remains unobstructed and thus endocytosis of
the complex should be unaltered, unlike other studies using
random derivations.25
The CTB-functionalised nanoparticles (2 mL of 2.4 mM) were
injected via the tongue in mice to assess whether the nano-
conjugates could be endocytosed and transported in a retro-
grade direction in vivo. Silver enhanced brainstem slices
revealed that the nano-conjugates were in neurons of the
hypoglossal nucleus after injection (Fig. 4a). Staining was found
optimal when using azido-CTB conjugated to nanoparticles
prepared using 25% of the active DHLA-PEG11-cyclooctyne
ligand as shown in Fig. 3. Given the reduced amount of
CTB–nanoparticles delivered versus azido-CTB, there are fewer
labelled cells. These nanoparticles were not detected in mice
injected with just nanoparticles (Fig. 4b), indicating that they
cannot transport in a retrograde manner without CTB. The
silver enhanced slices were then prepared for EM where puncta
corresponding to the metal deposits were found to be mainly
localised to lysosomes (Fig. 4c). While CTB is known to travel
in a retrograde manner to the Golgi,26,27 the appearance of
CTB–nanoparticle conjugates in the lysosome is also in agree-
ment with other studies,28,29 and may be the final fate of CTB
after longer periods in vivo. Nonetheless, the easy application of
azido-CTB as a nanoparticle-conjugate could further improve
its use as a neuronal tracer for EM analysis. It does not require
cellular permeabilisation, and thus avoids damage to cellular
membranes, which occurs when using agents such as Triton
X-100 or ethanol to allow penetrance of antibodies. The easy
detection of CTB–nanoparticle conjugates via correlated light
microscopy and EM, thus provides a much wider scope for
possible experiments with tissue. These experiments highlight
that alkynated substances can be readily and efficiently ‘‘clicked’’
onto azido-CTB prior to injection, increasing the possibility for
rapid testing of CTB as a powerful delivery vehicle to carry different
cargoes into neurons.
In summary, azido-CTB presents a useful tool for diversifying
and enhancing its use as both a tracer and a delivery vehicle
compared to current commercially available CTB conjugates due
to ease of directed conjugation via CuAAC and SPAAC. Azido-CTB
may be further developed to create interchangeable conjugated
proteins via click chemistry; it could deliver multiple cargoes at
once, or cargo along with a reporter dye or even a nanoparticle.
This has been proven with CTB–nanoparticle conjugates pro-
duced from azido-CTB; where the nanoparticles were detectable
after injection in vivo. Azido-CTB presents a diverse tool for
tracing that is subsequently detected both with fluorescence
Fig. 3 Preparation of CTB–nanoparticle-based neuronal tracers for
detection by electron microscopy. Azido-CTB was conjugated via SPAAC
to dihydrolipoic acid-PEG11-cyclooctyne-functionalised CdSe/ZnS nano-
particles prepared with 10% (n :m = 1 : 9) or 25% (n :m = 1 : 3) of the active
ligand. It is assumed that the final ligand composition on the nanoparticles
is comparable to that of the mixture of DHLA ligands used in their
preparation.
Fig. 4 Use of CTB–nanoparticles as neuronal tracers for detection by
electron microscopy. (a) Hypoglossal nucleus (dotted lines) having under-
gone silver enhancement, inset shows enlarged positive neurons.
(b) Control brainstem slice from uninjected mouse having undergone silver
enhancement. (c) Electron microscopy of hypoglossal nucleus cell (ci) and
lysosomes inside that cell (cii). Labelling is confined to these structures. Scale
bars: a and b = 100 mm; a inset = 25 mm; ci = 0.5 mm; cii = 0.2 mm.
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and EM, for use in live and fixed tissue, and for use in extended
time-lapse experiments. Moreover, other theranostic functions
can be readily incorporated via conjugating to other functional
nanoparticles (e.g. magnetic nanoparticles for magnetic reso-
nance imaging;30 gold nanorods for photothermal treatment
and/or photoacoustic imaging).31,32 With the increasing array of
molecules and nanoparticles able to be ‘clicked’ to azides, there
is a wide scope of opportunity for azido-CTB to be utilised for
efficient and rapid attachment of novel tracers, cargoes and/or
incorporating with multiple theranostic functions.
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